Skip to main content
Fig. 2 | Molecular Neurodegeneration

Fig. 2

From: Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

Fig. 2

a Plots for the concentrations of plasma p-tau181 in the control patients (n = 15) and the clinically diagnosed patients with AD (n = 20) of Cohort 1. The solid lines represent the mean value ± standard errors (SE) of the concentrations of each group. The concentration of plasma p-tau181 in the AD group was significantly higher than that in the age-matched control subjects (p = 0.0039, Mann–Whitney U test). The dashed line corresponds to the cut-off value of the plasma p-tau181 to discriminate those two groups (0.0921 pg/ml). b ROC analysis of the levels of plasma p-tau181 for the discrimination between AD and control groups (AUC = 0.786, sensitivity = 60.0%, specificity = 85.7%)

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326